Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
Ceritinib following crizotinib relapse for ALK positive NSCLC

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 1512

Dr Giorgio Scagliotti - University of Turin, Turin, Italy

Dr Scagliotti presents, at a press conference at ESMO 2016, results from the ASCEND-5 trial of ceritinib, a kinase inhibitor targeting ALK rearrangements, for patients with advanced non-small cell lung cancer who had relapsed following crizotinib therapy.

He spoke with ecancer about these results, with a video interview available here.

Further details are available in news coverage here.

NSCLC was discussed further in this press conference by Dr Martin Reck, Dr Corey Langer, and Dr Fabrice Barlesi.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation